Prostatype Genomics Revenue vs. Return On Asset
| PROGEN Stock | SEK 12.00 0.60 5.26% |
For Prostatype Genomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Prostatype Genomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Prostatype Genomics AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Prostatype Genomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Prostatype Genomics AB over time as well as its relative position and ranking within its peers.
Prostatype |
Prostatype Genomics Return On Asset vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Prostatype Genomics's current stock value. Our valuation model uses many indicators to compare Prostatype Genomics value to that of its competitors to determine the firm's financial worth. Prostatype Genomics AB is rated top company in revenue category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Prostatype Genomics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Prostatype Genomics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Prostatype Revenue vs. Competition
Prostatype Genomics AB is rated top company in revenue category among its peers. Market size based on revenue of Diagnostics & Research industry is at this time estimated at about 35.57 Million. Prostatype Genomics adds roughly 10,001 in revenue claiming only tiny portion of equities under Diagnostics & Research industry.
Prostatype Return On Asset vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Prostatype Genomics |
| = | 10 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Prostatype Genomics |
| = | -0.39 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Prostatype Return On Asset Comparison
Prostatype Genomics is currently under evaluation in return on asset category among its peers.
Prostatype Genomics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Prostatype Genomics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Prostatype Genomics will eventually generate negative long term returns. The profitability progress is the general direction of Prostatype Genomics' change in net profit over the period of time. It can combine multiple indicators of Prostatype Genomics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. The company was founded in 2007 and is based in Solna, Sweden. Prostatype Genomics is traded on Stockholm Stock Exchange in Sweden.
Prostatype Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Prostatype Genomics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Prostatype Genomics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Prostatype Genomics' important profitability drivers and their relationship over time.
Use Prostatype Genomics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Prostatype Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Prostatype Genomics will appreciate offsetting losses from the drop in the long position's value.Prostatype Genomics Pair Trading
Prostatype Genomics AB Pair Trading Analysis
The ability to find closely correlated positions to Prostatype Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Prostatype Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Prostatype Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Prostatype Genomics AB to buy it.
The correlation of Prostatype Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Prostatype Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Prostatype Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Prostatype Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Prostatype Genomics position
In addition to having Prostatype Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large & Mid Caps ETFs Thematic Idea Now
Large & Mid Caps ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Large & Mid Caps ETFs theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large & Mid Caps ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Prostatype Stock
To fully project Prostatype Genomics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Prostatype Genomics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Prostatype Genomics' income statement, its balance sheet, and the statement of cash flows.